
| Hydroxychloroquine in Covid-19: Does the end justify the means? #MMPMID32340837Yakoub-Agha ICurr Res Transl Med 2020[Aug]; 68 (3): 81-82 PMID32340837show ga
?|Antibody Formation/*drug effects[MESH]|Antiviral Agents/therapeutic use[MESH]|Azithromycin/administration & dosage/adverse effects[MESH]|Betacoronavirus/drug effects/physiology[MESH]|COVID-19[MESH]|COVID-19 Drug Treatment[MESH]|Cardiovascular Diseases/chemically induced/epidemiology[MESH]|Coronavirus Infections/complications/*drug therapy/epidemiology/*immunology[MESH]|Drug Therapy, Combination/adverse effects[MESH]|Humans[MESH]|Hydroxychloroquine/administration & dosage/*adverse effects/pharmacology[MESH]|Immunity, Cellular/*drug effects[MESH]|Immunity, Herd/*drug effects[MESH]|Immunosuppressive Agents/adverse effects/therapeutic use[MESH]|Pandemics[MESH]|Pneumonia, Viral/complications/*drug therapy/epidemiology/*immunology[MESH]|SARS-CoV-2[MESH]|Viral Load/drug effects[MESH]
  
DeepDyve Pubget Overpricing | 
|